Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 38.48M 27.61M 23.93M 22.61M 20.53M 2.65B 38.71M 270M 104M 1.34B 104M 101M 4.28B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 38.25M 27.44M 23.78M 22.48M 20.41M 2.63B 38.48M 268M 104M 1.34B 103M 101M 4.26B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
10/08 Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing CI
25/07 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026 CI
19/06 Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility CI
10/06 Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project CI
05/06 Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding CI
01/05 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding CI
01/05 Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026 CI
24/04 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026 CI
28/03 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025 CI
27/03 Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt CI
24/03 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding CI
05/03 Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient CI
24/02 Voyageur Pharmaceuticals Announces Collaboration with Bayer Aktiengesellschaft CI
1 day+3.03%
1 week+6.25%
1 month+6.25%
3 months+78.95%
6 months+13.33%
1 week 0.16
Extreme 0.155
0.17
1 month 0.16
Extreme 0.155
0.18
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.2
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Date Insider Type Main position Quantity % Market Cap. Importance
16/3/26 Option 16,367 0.0092% -
16/3/26 Other 0 0% -
9/3/26 Option

Executive/Senior Manager

150,000 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%+6.25%+3.03%+209.09% 27.61M
+0.15%+1.21%+48.79%+97.65% 1,014B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 464B
-1.01%+3.73%+37.63%+38.94% 354B
+0.94%+2.80%+19.36%+25.28% 265B
+1.03%+4.39%+7.70%+14.41% 253B
+0.19%-3.81%+37.81%+44.35% 203B
+0.17%-4.70%-26.16%-58.05% 186B
+0.94%+1.39%+33.21%+95.16% 183B
Average +0.67%+1.49%+23.42%+60.50% 356.68B
Weighted average by Cap. +0.39%+1.41%+34.16%+60.19%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.41 0.03 0.03 1.3
Net income -1.71M -1.22M -1.06M -1M -911K -118M -1.72M -11.98M -4.63M -59.61M -4.6M -4.5M -190M -3.53M -2.53M -2.2M -2.08M -1.88M -243M -3.55M -24.79M -9.58M -123M -9.52M -9.31M -393M
Net Debt -113K -80.82K -70.04K -66.2K -60.1K -7.75M -113K -790K -305K -3.93M -304K -297K -12.53M -231K -165K -143K -135K -123K -15.87M -232K -1.62M -625K -8.05M -621K -608K -25.66M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
16/09/26 CAD 0.1700 +3.03% 162,500
15/09/26 CAD 0.1650 0.00% 66,402
14/09/26 CAD 0.1650 0.00% 159,080
11/09/26 CAD 0.1650 +3.13% 139,055
10/09/26 CAD 0.1600 0.00% 85,182

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!